Jeffrey Alan Jones - 28 Feb 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Medical Officer
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
28 Feb 2022
Net transactions value
$0
Form type
4
Filing time
02 Mar 2022, 18:05:49 UTC
Next filing
21 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +215,000 $0.000000 215,000 28 Feb 2022 Common Stock 215,000 $14.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option represents a right to purchase a total of 215,000 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on February 28, 2023, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.